Fig. 1. ATF4 is overexpressed in pancreatic cancer and is associated with poor prognosis in patients with PDAC.
A ATF4 expression profile across all tumor samples and corresponding normal tissues in the TCGA database. B Combined analysis of ATF4 expression in pancreatic cancer tissues and corresponding normal tissues from TCGA and GTEx databases. C qRT-PCR analysis of ATF4 expression levels in 60 PDAC tissue samples and paired normal adjacent tissue samples collected in our hospital. ***p < 0.001. D qRT-PCR assay was performed to detect the mRNA expression of ATF4 in the pancreatic normal ductal epithelial cell line HPDE6-C7 and cancer lines including AsPC-1, BxPC-3, Capan-2, CFPAC-1, MIA PaCa-2, PANC-1, and SW1990. n = 3. E Western blot assay showing the protein expression level of ATF4 in a pancreatic normal ductal epithelial cell line and cancer cell lines. F Representative IHC staining images showed negative (−), weakly positive (+), moderate positive (++), and strongly positive (+++) expression of ATF4 in pancreatic cancer tissue samples. G Kaplan–Meier survival analysis was performed to compare ATF4-high and ATF4-low PDAC patients’ progression-free survival times from our hospital. N = 52, log-rank test. H Kaplan–Meier survival analysis was performed to compare ATF4-high and ATF4-low PDAC patients’ overall survival times from our hospital. N = 52, log-rank test.